Elliott Parker argues corporates are bad at innovation because they’re optimised for efficiency. Here’s what they should do instead.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Aurion Biotech advances with $120m
Alcon was among the participants in a round representing the first funding to be disclosed by the cellular ophthalmology therapeutics developer.
V-Bio Ventures finalises Fund 2
Venture capital firm V-Bio Ventures has reached the final close of its second fund, with Vanden Avenue Commodities among the limited partners.
Source Global captures $150m
Duke Energy is among the investors in Source Global, which has created panels that generate clean drinking water from sunlight and water vapour.
Texas Medical Center takes fund to $75m
The healthcare provider has added $50m to its original commitment of $25m for TMC Venture Fund, to be deployed over the next decade.
Scipher Medicine unlocks $110m
Hitachi Ventures and Optum Ventures contributed to a $110m round for precision immunology technology developer Scipher, already backed by Echo Health Ventures.
UTokyo IPC achieves $221m close
Daikin Industries, Hakuhodo, Zeon, Fuyo General Lease, Mitsubishi Estate and several banks helped University of Tokyo’s venture arm close its second fund.
Scandit captures $150m in series D round
GV, Sony Innovation Fund, Schneider Electric and Swisscom Ventures helped data capture technology producer Scandit raise money at a valuation topping $1bn.
ImmPact Bio forges ahead with $111m
Bukwang Pharmaceutical and Novartis Venture Fund were among the latest investors in the developer of T-cell therapies for liquid and solid cancers.
Korro Bio concludes $116m series B
All existing shareholders including Alexandria Venture Investments contributed to the RNA drug developer’s series B round, following a $91.5m series A in mid-2020.
AviadoBio accesses $80m in series A funding
AviadoBio is focusing on neurodegenerative diseases and has emerged from stealth with nearly $100m in total from investors including Johnson & Johnson Innovation – JJDC.
Commonwealth Fusion Systems sparks $1.8bn series B
Eni, GV and Equinor Ventures were among the investors in a round billed as the largest so far for a nuclear fusion technology developer.
Ieso institutes $53m series B round
Sony Innovation Fund took part in a series B round for the digital medicine technology developer as it seeks to expand in the UK and US.
Blade to get a slice of Nasdaq action
Bristol Myers Squibb and Pfizer Ventures are part of a PIPE financing backing the fibrosis and neurodegenerative disease drug developer’s reverse takeover.